Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma.

6 ), although there is a trend for better overall survival but it did not reach statistical significance.

also in 111,027 other papers

When ST3GAL1 was silenced in the Huh7 sorafenib-resistant cells, cetuximab induced a highly significant increases in the percentages of CD107a (Fig. 5 b) and IFN-g (Fig. 5 c) on PBNKS, as compared to pVoid transfected Huh7 sorafenib-resistant cells.

also in 132,142 other papers